Macedonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
alpha glucosidase/мачнина
Врската е зачувана во таблата со исечоци
11 резултати
Safety profile of acarbose, an alpha-glucosidase inhibitor.
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
Acarbose, an alpha-glucosidase inhibitor, delays absorption of carbohydrate in the gut, thereby lowering postprandial glucose levels. Safety data on this drug have been gathered in a series of studies on animals and in extensive clinical trials in humans. Although an initial long term feeding study
DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
BACKGROUND
Alpha glucosidase inhibitor (GI) attenuates postprandial hyperglycemia (PPH) and reduces the risk of cardiovascular events in patients with impaired glucose tolerance or type 2 diabetes. Dipeptidyl peptidase 4 (DPP-4) inhibitors also attenuate PPH. PPH is one of the factors leading to
Pneumatosis cystoides intestinalis induced by the alpha-glucosidase inhibitor complicated from sigmoid volvulus in a diabetic patient.
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
Noninsulin treatment of type 2 diabetes mellitus in geriatric patients: a review.
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
BACKGROUND
Currently, 42% of the US population with diabetes is aged ≥65 years.
OBJECTIVE
The aim of this review was to discuss the efficacy and tolerability of noninsulin therapies for type 2 diabetes mellitus (T2DM), with an emphasis on patients aged ≥65 years.
METHODS
PubMed and EMBASE
Three diabetic cases of acute dizziness due to initial administration of voglibose.
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
We observed 3 diabetic patients with intolerable dizziness followed by nausea and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor, voglibose. These symptoms did not recur after discontinuation of the drug. Adverse effects as observed in these cases have not
Albuterol as an adjunctive treatment to enzyme replacement therapy in infantile-onset Pompe disease.
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
BACKGROUND
Early initiation of enzyme replacement therapy (ERT) with recombinant human acid alpha-glucosidase is an effective treatment for patients with infantile-onset Pompe disease (IOPD) but cannot prevent a slow progression of myopathy. Albuterol has been shown to be helpful in adult patients
A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease.
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
Late-onset Pompe disease is a rare genetic neuromuscular disorder caused by lysosomal acid alpha-glucosidase (GAA) deficiency that ultimately results in mobility loss and respiratory failure. Current enzyme replacement therapy with recombinant human (rh)GAA has demonstrated efficacy in subjects with
Glucose-lowering treatment of type 2 diabetes. Part II--Glucose-lowering drugs after metformin: a choice based largely on adverse effects.
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
Metformin alone is the glucose-lowering drug of first choice for patients with type 2 diabetes. None of the other glucose-lowering drugs available in 2014 have any proven efficacy in preventing diabetes complications. How important are adverse effects in the choice of glucose-lowering alternatives
Safety, tolerability and efficacy of lixisenatide in combination with oral antidiabetic treatment in Japanese patients with type 2 diabetes: An open-label, multicenter study.
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
UNASSIGNED
To assess the overall safety and efficacy of lixisenatide in combination with background oral antidiabetic drug treatment in Japanese patients with type 2 diabetes, as required by Japanese guidelines.
METHODS
A phase 3, multicenter, uncontrolled, open-label, four-arm, parallel-group study
A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trial.
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
The goal of this study was to assess the safety and efficacy of 0.75 mg of dulaglutide, a once weekly glucagon-like peptide-1 receptor agonist, in Japanese patients with type 2 diabetes (T2D) on a single oral hypoglycemic agent (OHA). In this phase 3, nonrandomized, open-label, parallel-group,
[Occurrence of ileus after voglibose treatment in an elderly diabetic patient with gait disturbance caused by cerebral hemorrhage].
Само регистрираните корисници можат да преведуваат статии
Пријавете се / пријавете се
Alpha-glucosidase inhibitor can suppress postprandial hyperglycemia by delaying the absorption of carbohydrates in the intestine, and may be useful in obese patients with non-insulin-dependent diabetes mellitus (NIDDM) and preserved insulin secretion. We encountered an obese elderly patient with
Најкомплетната база на податоци за лековити билки поддржана од науката
- Работи на 55 јазици
- Лекови од билки поддржани од науката
- Препознавање на билки по слика
- Интерактивна GPS мапа - означете ги билките на локацијата (наскоро)
- Прочитајте научни публикации поврзани со вашето пребарување
- Пребарувајте лековити билки според нивните ефекти
- Организирајте ги вашите интереси и останете во тек со истражувањето на новостите, клиничките испитувања и патентите
Напишете симптом или болест и прочитајте за билки што можат да помогнат, напишете билка и видете болести и симптоми против кои се користи.
* Сите информации се базираат на објавени научни истражувања
